A new approach to prevent, diagnose, and treat hepatitis B in Africa

There are 82 million people living with hepatitis B (PLWHB) in the World Health Organization Africa region, where it is the main cause of liver disease. Effective vaccines have been available for over 40 years, yet there are 990,000 new infections annually, due to limited implementation of hepatitis...

Full description

Saved in:
Bibliographic Details
Published in:BMC global and public health 2023-11, Vol.1 (1), p.24, Article 24
Main Authors: Spearman, C Wendy, Andersson, Monique I, Bright, Bisi, Davwar, Pantong M, Desalegn, Hailemichael, Guingane, Alice Nanelin, Johannessen, Asgeir, Kabagambe, Kenneth, Lemoine, Maud, Matthews, Philippa C, Ndow, Gibril, Riches, Nicholas, Shimakawa, Yusuke, Sombié, Roger, Stockdale, Alexander J, Taljaard, Jantjie J, Vinikoor, Michael J, Wandeler, Gilles, Okeke, Edith, Sonderup, Mark
Format: Article
Language:English
Subjects:
Humanities and Social Sciences
Life Sciences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are 82 million people living with hepatitis B (PLWHB) in the World Health Organization Africa region, where it is the main cause of liver disease. Effective vaccines have been available for over 40 years, yet there are 990,000 new infections annually, due to limited implementation of hepatitis B birth dose vaccination and antenatal tenofovir prophylaxis for highly viraemic women, which could eliminate mother-to-child transmission. Despite effective and cheap antiviral treatment which can suppress hepatitis B virus replication and reduce the risk of hepatocellular carcinoma (HCC), 
ISSN:2731-913X
2731-913X
DOI:10.1186/s44263-023-00026-1